Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical (BMRN) reported $874.57 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 17%. EPS of $0.46 for the same period compares to $0.92 a year ago.

The reported revenue represents a surprise of +5.41% over the Zacks Consensus Estimate of $829.66 million. With the consensus EPS estimate being $0.25, the EPS surprise was +85.48%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net product revenues: $859.32 million versus the 10-analyst average estimate of $813.04 million. The reported number represents a year-over-year change of +16.8%.
• Revenues- Royalty and other revenues: $15.24 million versus the 10-analyst average estimate of $13.32 million. The reported number represents a year-over-year change of +30.5%.
• Revenues- Net Product Revenues- NAGLAZYME: $120 million versus the nine-analyst average estimate of $123.94 million. The reported number represents a year-over-year change of +9.1%.
• Revenues- Net Product Revenues- VIMIZIM: $206 million versus $201.47 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
• Revenues- Net Product Revenues- PALYNZIQ: $125 million compared to the $108 million average estimate based on nine analysts. The reported number represents a change of +25% year over year.
• Revenues- Net Product Revenues- VOXZOGO: $273 million versus the nine-analyst average estimate of $262.31 million. The reported number represents a year-over-year change of +31.3%.
• Revenues- Net Product Revenues- KUVAN: $23 million versus the nine-analyst average estimate of $20.82 million. The reported number represents a year-over-year change of -17.9%.
• Revenues- Net Product Revenues- ALDURAZYME: $49 million versus $44.95 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +25.6% change.
• Revenues- Net Product Revenues- BRINEURA: $49 million compared to the $47.51 million average estimate based on nine analysts. The reported number represents a change of +2.1% year over year.
• Revenues- Net Product Revenues- ROCTAVIAN: $13 million compared to the $7.58 million average estimate based on eight analysts. The reported number represents a change of +18.2% year over year.

View all Key Company Metrics for BioMarin here>>>

Shares of BioMarin have returned +14% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include

Stock #1: A Disruptive Force with Notable Growth and Resilience

Stock #2: Bullish Signs Signaling to Buy the Dip

Stock #3: One of the Most Compelling Investments in the Market

Stock #4: Leader In a Red-Hot Industry Poised for Growth

Stock #5: Modern Omni-Channel Platform Coiled to Spring

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.

See Our Newest 5 Stocks Set to Double Picks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research